This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
All You Need to Know About Phreesia (PHR) Rating Upgrade to Buy
by Zacks Equity Research
Phreesia (PHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Phreesia (PHR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Phreesia (PHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's What Key Metrics Tell Us About Phreesia (PHR) Q1 Earnings
by Zacks Equity Research
The headline numbers for Phreesia (PHR) give insight into how the company performed in the quarter ended April 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 46.15% and 1.09%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Phreesia (PHR) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Phreesia (PHR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended April 2025.
Privia Health (PRVA) Misses Q1 Earnings Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -50% and 5.37%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
TruBridge (TBRG) Lags Q1 Earnings Estimates
by Zacks Equity Research
TruBridge (TBRG) delivered earnings and revenue surprises of -2.70% and 1.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Phreesia (PHR) Could Surge 28.02%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 28% upside potential for Phreesia (PHR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Company News for Mar 14, 2025
by Zacks Equity Research
Companies in The News Are: QBTS, INTC, DG, PHR
Phreesia (PHR) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Phreesia (PHR) give a sense of how the business performed in the quarter ended January 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 42.11% and 0.71%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?
The Pennant Group, Inc. (PNTG) Q4 Earnings Miss Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of -4% and 1.12%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Moves 5.6% Higher: Will This Strength Last?
by Zacks Equity Research
Phreesia (PHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Phreesia, Inc. (PHR) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Phreesia (PHR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Industry Outlook Enovis, Omnicell and Phreesia
by Zacks Equity Research
Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article.
3 Medical Info Systems Stocks to Buy as Stargate AI Drives Industry Prospects
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Enovis, Omnicell and Phreesia are expected to gain from the GenAI wave.
Phreesia (PHR) Upgraded to Buy: Here's Why
by Zacks Equity Research
Phreesia (PHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should You Buy Phreesia (PHR) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Wall Street Analysts See a 25% Upside in Phreesia (PHR): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 25% upside potential for Phreesia (PHR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Phreesia (PHR) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Phreesia (PHR) give a sense of how the business performed in the quarter ended October 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 13.79% and 0.76%, respectively, for the quarter ended October 2024. Do the numbers hold clues to what lies ahead for the stock?
Curious about Phreesia (PHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Phreesia (PHR) for the quarter ended October 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
SolGel Technologies (SLGL) delivered earnings and revenue surprises of 92.31% and 99.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -18.52% and 41.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of -30% and 13.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?